Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1991 1
1992 2
1993 1
1999 1
2000 1
2001 2
2002 1
2005 1
2006 1
2007 2
2008 2
2009 1
2012 1
2013 1
2014 2
2015 1
2016 2
2017 4
2018 3
2019 2
2020 8
2021 2
2022 3
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer.
Steinberg GD, Shore ND, Redorta JP, Galsky MD, Bedke J, Ku JH, Kretkowski M, Hu H, Penkov K, Vermette JJ, Tarazi JC, Randall AE, Pierce KJ, Saltzstein D, Powles TB. Steinberg GD, et al. Among authors: saltzstein d. Future Oncol. 2024 May;20(14):891-901. doi: 10.2217/fon-2023-0271. Epub 2024 Jan 8. Future Oncol. 2024. PMID: 38189180 Free article.
Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
Tutrone R, Saad F, George DJ, Tombal B, Bailen JL, Cookson MS, Saltzstein DR, Hanson S, Brown B, Lu S, Fallick M, Shore ND. Tutrone R, et al. Among authors: saltzstein dr. Eur Urol Oncol. 2023 Dec 23:S2588-9311(23)00290-0. doi: 10.1016/j.euo.2023.11.024. Online ahead of print. Eur Urol Oncol. 2023. PMID: 38143206 Free article.
Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer.
Shore ND, Polikarpov DM, Pieczonka CM, Henderson RJ, Bailen JL, Saltzstein DR, Concepcion RS, Beebe-Dimmer JL, Ruterbusch JJ, Levin RA, Wissmueller S, Le TH, Gillatt DA, Chan DW, Deng N, Siddireddy JS, Lu Y, Campbell DH, Walsh BJ. Shore ND, et al. Among authors: saltzstein dr. Urol Oncol. 2023 Nov;41(11):454.e9-454.e16. doi: 10.1016/j.urolonc.2023.08.005. Epub 2023 Sep 19. Urol Oncol. 2023. PMID: 37734979
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
Shore ND, Mehlhaff BA, Cookson MS, Saltzstein DR, Tutrone R, Brown B, Lu S, Fallick M, Hanson S, Saad F. Shore ND, et al. Among authors: saltzstein dr. Adv Ther. 2023 Nov;40(11):4919-4927. doi: 10.1007/s12325-023-02634-7. Epub 2023 Sep 15. Adv Ther. 2023. PMID: 37713020 Free PMC article. Clinical Trial.
Reply by Authors.
Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM. Jani AB, et al. Among authors: saltzstein d. J Urol. 2023 Aug;210(2):310-311. doi: 10.1097/JU.0000000000003493.02. Epub 2023 Jul 7. J Urol. 2023. PMID: 37416959 No abstract available.
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply.
Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM. Jani AB, et al. Among authors: saltzstein d. J Urol. 2023 Sep;210(3):411-412. doi: 10.1097/JU.0000000000003598. Epub 2023 Jun 23. J Urol. 2023. PMID: 37350185 No abstract available.
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM; SPOTLIGHT Study Group. Jani AB, et al. Among authors: saltzstein d. J Urol. 2023 Aug;210(2):299-311. doi: 10.1097/JU.0000000000003493. Epub 2023 Apr 26. J Urol. 2023. PMID: 37126069
50 results